Highly active antiretroviral therapy
A new study conducted by researchers from the University of Copenhagen and the Centre of Excellence for Health, Immunity Infections (CHIP) has found an association between the use of raltegravir, an integrase strand-transfer inhibitor (INSTI), and higher mortality rates in HIV patients. The study, published in eClinicalMedicine, analyzed data from
AIDS treatment
Research conducted by a team from the University of California San Francisco (UCSF) has found that early testing of infants exposed to HIV can significantly decrease mortality rates for those linked to HIV treatment. According to the study, infants exposed to HIV should be tested at 6 weeks of age,
Elderly
A Dutch study presented at the 20th European AIDS Conference in Paris compared the health-related quality of life (HRQoL) in around 500 older people with HIV with the same number of carefully matched people without HIV over the last decade. The study found that, although the people with HIV reported
Diseases
People living with HIV (PWH) who have complex health conditions are at a high risk of developing skin problems, such as infectious dermatoses, inflammatory dermatoses, or cutaneous malignancies (CM). According to a study published in the Journal of the American Academy of Dermatology, the incidence of dermatologic disease (DD) has
Diseases
People living with HIV (PWH) who have complex health conditions are at a high risk of developing skin problems, such as infectious dermatoses, inflammatory dermatoses, or cutaneous malignancies (CM). According to a study published in the Journal of the American Academy of Dermatology, the incidence of dermatologic disease (DD) has
AIDS treatment
The prevalence of skin conditions among people living with HIV remains significant, even in the era of highly effective antiretroviral therapy. A new study published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, reveals that nearly half of participants experienced skin conditions. The
AIDS treatment
The prevalence of skin conditions among people living with HIV remains significant, even in the era of highly effective antiretroviral therapy. A new study published through the DC Cohort, one of the largest HIV longitudinal studies in the United States, reveals that nearly half of participants experienced skin conditions. The
HIV
South Africa's Health Minister, Dr. Aaron Motsoaledi, has announced plans to roll out lenacapavir, a long-acting injectable HIV prevention method, as early as March 2026. Lenacapavir offers six months of protection with just two annual doses and has shown remarkable efficacy in clinical trials, with 100% protection among
HIV
A new study by researchers at the George Washington University has found that nearly half of people living with HIV experience skin conditions, despite the advances in HIV treatment. The study, which examined medical records from 11,738 adults in Washington, D.C., between 2011 and 2023, highlights the need
HIV
South African Health Minister Dr. Aaron Motsoaledi announced plans to roll out a long-acting HIV prevention method, lenacapavir, by March 2026. This innovative approach offers six months of protection with just two annual doses, addressing critical gaps in current prevention methods. The Minister emphasized that lenacapavir is a timely and
HIV
A new study by researchers at the George Washington University has found that nearly half of people living with HIV experience skin conditions, despite the advances in HIV treatment. The study, which examined medical records from 11,738 adults in Washington, D.C., between 2011 and 2023, highlights the need
Highly active antiretroviral therapy
Research has shown that disrupting services provided by the Ryan White HIV/AIDS Program could lead to a significant increase in HIV infections in the United States. According to a study published in the Annals of Internal Medicine in 2025, ending Ryan White services in July 2025 could result in
